ReNerve

ASX Announcement

17 November 2026

First patient in India receives ReNerve's NervAlign® Nerve Cuff

Highlights

- **First patient in India treated with the NervAlign® Nerve Cuff**, converting the Company's CDSCO marketing approval[2] into clinical use
- India is a major market opportunity for ReNerve as the world's most populous country, with approximately 1.45 billion people and a high incidence of road-trauma related peripheral nerve injuries[2]
- Achieved with ReNerve's Indian commercialisation partner, **NetCentrix Ventures**[1], after receiving India's first marketing approval for the Company[2]
- Follows **record September 2026 quarter sales of $584,000**, up 176% on the June quarter and exceeding ReNerve's full-year FY26 sales, with September the Company's first month above $200,000[3]
- Adds to a growing Asia-Pacific footprint, following first cases in Hong Kong and Malaysia[6] and marketing approval in Indonesia[5]

ReNerve Limited (ASX: RNV, "ReNerve" or "the Company"), an Australian medical device company developing innovative products for peripheral nerve injury (PNI) repair, is pleased to announce that the first patient in India has received its FDA-cleared NervAlign® Nerve Cuff, marking the transition from regulatory approval to commercial use in one of the world's largest healthcare markets.

The procedure was performed in Bangalore for an upper extremity nerve repair. The case is the first commercial use of the NervAlign® Nerve Cuff in India and follows the Central Drugs Standard Control Organisation (CDSCO) marketing approval announced on 10 August 2026, ReNerve's first product approval in the country[2].

The NervAlign® Nerve Cuff is a bioabsorbable protective wrap designed to support and protect nerves during healing following peripheral nerve injury or surgical repair. The post-operative feedback is very positive from both surgeon and patient, with the patient recovering well with no post-operative issues.

ReNerve entered its partnership with NetCentrix Ventures in April 2025 to secure regulatory approval for, and commercialise, the NervAlign® Nerve Cuff in India[1]. With CDSCO approval achieved, the partners are now progressing a coordinated commercialisation strategy tailored to the Indian healthcare system[2].

NetCentrix provides local regulatory expertise and established distribution networks and has commenced surgeon education and product in-servicing across India. ReNerve is providing clinical and technical support, training and regulatory liaison, with further cases scheduled over the coming weeks.

India's population of approximately 1.45 billion, combined with a high incidence of road-trauma related nerve injuries, underpins a large and growing addressable patient base. The Indian nerve repair market has been estimated at approximately US$700 million[2].

ReNerve CEO Dr Julian Chick said:

> *"The first nerve repair case in India with the NervAlign® Nerve Cuff is a significant moment for ReNerve. Regulatory approval opened the door in August, and this case shows our partnership with NetCentrix is turning that approval into surgeons using the product in the operating theatre.*
>
> *"India has the largest population in the world and a high incidence of trauma (road, industrial, agricultural) related nerve injuries, which means a very large number of patients who may benefit from better nerve repair options.*
>
> *"This milestone builds on our strongest quarter to date, with September quarter sales of $584,000 already ahead of the whole of FY26. With a growing US business, new Empliq® revenue and now first cases across Hong Kong, Malaysia and India, we have multiple engines driving growth."*

ReNerve expects to provide further updates as case volumes build in India, and as the Company progresses commercial entry into Indonesia and the Philippines5. The Company continues to advance the NervAlign® Nerve Guide Matrix through Stage 3 of its four-stage development program, targeting completion by the end of calendar 2026, and the NervAlign® Nerve Conduit through commercial scale-up ahead of market launch[3,4].

The first Indian case comes as ReNerve's sales continue to accelerate. During the September 2026 quarter the Company:

- Delivered **record quarterly sales of $584,000**, up 176% on the June 2026 quarter ($211,000) and 774% on the corresponding quarter last year[3];
- Achieved quarterly sales **exceeding the Company's full-year FY26 result** ($510,357), with September its first month of sales above $200,000[3]; and
- Continued to build its US distribution network, which stood at 21 partners at the end of FY26, alongside purchasing approvals across the **US Department of Defence and Veterans Affairs** healthcare systems and growing uptake of the **Empliq® human tissue range**[4].

In Asia-Pacific, the Company has now progressed from regulatory approval to clinical use in Hong Kong, Malaysia and India[2,6], and holds marketing approval in Indonesia[5]. ReNerve now has commercial activity across the United States, New Zealand, Hong Kong, Thailand, Malaysia, Indonesia, the Philippines and, with this first case, India[4].

ENDS -

This announcement has been approved for release by the Company's Board of Directors.

References

The following ASX announcements by ReNerve Limited are referred to in this release and are available at www.asx.com.au (ASX:RNV):

1. *ReNerve Expands Global Footprint with Strategic Partnership in India*, ASX announcement dated 10 April 2025
2. *ReNerve Secures Marketing Approval in India*, ASX announcement dated 10 August 2026
3. *Quarterly Activities Report for the Period Ended 30 September 2026*, ASX announcement dated 26 October 2026
4. *Annual Report – Financial Year Ended 30 June 2026*, ASX announcement dated 28 August 2026
5. *ReNerve Secures Marketing Approval in Indonesia,* ASX announcement dated 7 July 2026
6. *ReNerve completes first cases in Hong Kong and Malaysia*, ASX announcement dated 21 September 2026

Note: reference titles have been drawn from public reporting of the relevant announcements and should be checked against the exact titles and dates on the ASX announcements platform before release.

For further information and enquiries, please contact:

Dr Julian Chick
CEO & Managing Director
ReNerve Ltd
+61 (03) 9482 3940
info@renerve.com.au

Matthew Wright
Investor & Media Relations
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au

About ReNerve Limited (ASX:RNV)

ReNerve Limited (ASX:RNV) is an Australian medical device company developing products for peripheral nerve injury (PNI) repair. Founded by a neurosurgeon and medtech researchers, ReNerve is focused on ready-to-use solutions designed to support peripheral nerve surgery and improve patient outcomes. The Company's lead product is the FDA-cleared NervAlign® Nerve Cuff, complemented by the Empliq® range of human tissue products for surgical and wound-care applications. ReNerve's product pipeline includes the NervAlign® Nerve Conduit and the NervAlign® Nerve Guide Matrix, currently in development. ReNerve products are commercialised in the United States, New Zealand, Hong Kong, Thailand, Malaysia, Indonesia, the Philippines and India. For more information visit [www.renerve.com.au].